Skip to main content
. 2023 Apr 25;12(4):786–796. doi: 10.21037/tlcr-23-121

Figure 2.

Figure 2

Kaplan-Meier analysis of PFS in specific subgroups of patients stratified by age (A), ECOG performance status (B), histology (C), brain metastases (D), liver metastasis (E), and camrelizumab treatment line (F). PFS, progression-free survival; NR, not reached; ECOG, Eastern Cooperative Oncology Group; PS, performance status; SCC, squamous cell carcinoma; NSCC, non-squamous cell carcinoma.